Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track VMD with free AI briefings, catalyst countdowns, and dilution alerts.

VMD · VIEMED HEALTHCARE, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$9.7M Cash on Hand
CF+ Cash Runway
Follow VMD by email Get an email when VMD reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about VMD, unsubscribe in one click. Privacy

📣 What VMD Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

VMD holds $9.7M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VMD files for a raise →

👥 Who Owns VMD

Insiders 15.4% Institutions (225 holders) 72.5% Public and other holders 12.1%
HolderTypeShares% of sharesAs of
Casey Hoyt
Chief Executive Officer, Director · +392,246 options
Insider 2,335,407 6.16% 2026-01-29
Michael Moore
President · +426,222 options
Insider 2,294,018 6.05% 2026-09-24
William Todd Zehnder
Chief Operating Officer, Director · +436,438 options
Insider 390,309 1.03% 2026-01-29
Nitin Kaushal
Director · +15,217 options
Insider 161,361 0.43% 2026-08-17
Randy E. Dobbs
Director · +16,848 options
Insider 142,253 0.38% 2026-08-17
Trae Fitzgerald
Chief Financial Officer · +104,676 options
Insider 105,638 0.28% 2026-01-29
Jerome Cambre
Vice President of Sales · +91,632 options
Insider 104,088 0.27% 2026-01-29
Timothy Smokoff
Director · +15,217 options
Insider 90,547 0.24% 2026-08-17
Sabrina Heltz
Director · +15,217 options
Insider 82,520 0.22% 2026-08-17
William Frazier
Chief Medical Officer, Director · +52,485 options
Insider 73,214 0.19% 2026-06-25
Jeremy Trahan
General Counsel · +113,934 options
Insider 46,492 0.12% 2026-01-29

Share count 37,893,094 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full VMD picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VMD and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.